Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219795 | 0.94 | CNR2 (0.72) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL2219603 | 0.90 | CNR2 (0.63) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL2222092 | 0.90 | CNR2 (0.54) | CNR2CYP1A2CYP2C9CNR1 | |
| SCHEMBL923993 | 0.88 | CNR2 (0.67) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL923964 | 0.87 | CNR2 (0.72) | CNR2CYP1A2CYP2C9CNR1 | |
| SCHEMBL923098 | 0.87 | CNR2 (0.69) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL922933 | 0.84 | CNR2 (0.73) | CNR2CYP1A2CYP2C9CNR1 | |
| SCHEMBL2221205 | 0.83 | CNR2 (0.62) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL923000 | 0.83 | CNR2 (0.72) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL2219465 | 0.82 | CNR2 (0.64) | CNR2CYP1A2CYP2C9CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | claimed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | claimed |
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | disclosed |
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | disclosed |
| US-8309584-B2 | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2012-11-13 | — | — | US | disclosed |
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010035915-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010035915-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2010-04-01 | — | — | WO | disclosed |
| US-7662808-B2 | N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | CHRNA6, CHRNA10, CHRNA2 | CNR2 23/4885CYP1A2 688/4885CYP2C9 1361/4885 |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | CHRNA6, CHRNA10, CHRNA2 | CNR2 23/4885CYP1A2 695/4885CYP2C9 1358/4885 |
| US-20110178140-A1 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, GPR119 | CNR2 2/4885CYP1A2 1159/4885CYP2C9 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.